Coming Soon: Conexiant’s news site is becoming MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more.
Family Medicine
Partner With Us
Advertisement
Conexiant chevron_right Family Medicine chevron_right HIV Prevention Landscape Shifts PrEP Study Insights
From the Journals

HIV Prevention Landscape Shifts: PrEP Study Insights

Study reveals 50-fold increase in PrEP users over decade, with generic TDF/FTC dominating 53.4% of prescriptions by 2023 despite availability of newer branded options.

MDSpire News

Clinical Scorecard: HIV Prevention Landscape Shifts: PrEP Study Insights

At a Glance

CategoryDetail
ConditionHIV Prevention
Key MechanismsPreexposure prophylaxis (PrEP) using oral and injectable medications.
Target PopulationIndividuals at high risk for HIV infection.
Care SettingU.S. retail and mail order pharmacies.

Key Highlights

  • Annual PrEP users increased from 10,281 in 2013 to 505,730 in 2023.
  • Generic TDF/FTC accounted for 53.4% of PrEP prescriptions in 2023.
  • 88.6% of individuals prescribed PrEP were male.
  • The South had the highest percentage of PrEP users at 38.3%.
  • Assistance programs were utilized by 53.4% of branded TDF/FTC users.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Cumulative total of 1.1 million individuals prescribed PrEP from 2013 to 2023.

          99% of individuals prescribed PrEP received oral medications.

          Clinical Best Practices

            Related Resources & Content

            Daily News

            Stay up to date with the latest clinical headlines and other information tailored to your specialty.